thebench.bio #1 Ecosystem for the Bio-Tech Industry

Industry Daily Summary

Industry Daily Summary: What Happened on October 5, 2026

CSL and Alentis strike $1.56 billion deal for kidney and liver drug

Shionogi agreed to buy IntraBio for $2 billion, while GE HealthCare plans a $945 million purchase of radiopharmaceutical maker Sofie Biosciences.

  • Updated
  • Read from 11 articles, 9 publications
  • P +3

Today in brief

CSL and Alentis will jointly develop lixudebart in a partnership worth up to $1.56 billion, including $355 million upfront from CSL.12 Shionogi agreed to buy IntraBio for $2 billion, gaining Aqneursa, an approved treatment for Niemann-Pick disease type C and ataxia-telangiectasia.34 GE HealthCare plans to acquire Sofie Biosciences for $945 million in cash, adding radiopharmaceutical manufacturing sites.5

CSL takes a leading role in Alentis’ lixudebart program

CSL and Alentis Therapeutics signed an exclusive global partnership to develop and commercialize lixudebart, a claudin-1 drug candidate.26 CSL will pay $355 million upfront and fund development, including a planned Phase III trial in AAV-associated rapidly progressive glomerulonephritis and Phase II studies in focal segmental glomerulosclerosis and primary sclerosing cholangitis.16

Alentis could receive up to $1.2 billion in commercial milestones, bringing the stated deal value to about $1.56 billion.12 If lixudebart reaches the market, CSL and Alentis plan to split global profits 55% to 45%.26

Alentis reported that an interim analysis of 26 patients in the Phase II RENAL study found improved kidney filtration and reduced proteinuria after 24 weeks.2 The company also reported improved liver function after six weeks in a 41-patient Phase Ib study in advanced liver fibrosis.2

Shionogi’s $2 billion IntraBio deal adds Aqneursa

Shionogi agreed to acquire IntraBio for $2 billion, adding Aqneursa, which is approved in the United States for neurological symptoms associated with Niemann-Pick disease type C and for ataxia-telangiectasia.34 The FDA first approved Aqneursa for Niemann-Pick disease type C in 2024 and expanded its approved uses to ataxia-telangiectasia in September.4

The European Commission approved Aqneursa for Niemann-Pick disease type C earlier in 2026, while its review for ataxia-telangiectasia is ongoing.4 Shionogi said Aqneursa generated $67.8 million in fiscal 2025 revenue and that it expects the acquisition to close by year-end, pending regulatory reviews.4

Earlier in 2026, Shionogi bought global rights to Radicava for $2.5 billion as it builds its rare-disease business.4

GE HealthCare to buy Sofie for $945 million

GE HealthCare plans to acquire Sofie Biosciences for $945 million in cash, expanding its radiopharmaceutical manufacturing and distribution network for PET imaging.57 Sofie operates 15 contract manufacturing locations and a research facility, supported by 21 cyclotrons that produce radioactive isotopes used in imaging drugs.5

The companies already work together on Flyrcado, a cardiac PET imaging product launched in 2025, and Sofie also helps produce Pylarify and Neuraceq.5 GE HealthCare expects the deal to close in the first half of 2027, after which Sofie is expected to remain an independent supplier to existing customers.5

Sofie’s FAPI-74 tracer is in Phase III trials as a diagnostic for pancreatic cancer and gastroesophageal tumors.5 GE HealthCare co-develops the tracer and holds commercial rights outside the United States.5

Also worth knowing

  • Daiichi appointed John Tsai to lead global R&D, with a mandate to expand its oncology work beyond its DXd antibody-drug conjugate franchise.8

  • Adecto Pharmaceuticals stopped operating on September 30. Endpoints News, citing a source familiar with the decision, said Aviceda Therapeutics is preparing to shut down.9

  • Convatec CEO Mason said device launches are accelerating for 2026 and 2027 and that he plans to increase R&D spending.10

  • M

    Exin Therapeutics plans a neurotherapeutics laboratory in the Philippines. The first phase has a ₱45 million budget and is designed to produce 10 drug candidates a month.11

Also published